香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Hansoh Pharmaceutical Group Company Limited 翰 森 製 藥 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：3692） 截至二零二二年十二月三十一日止年度 的年度業績公告 翰森製藥集團有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公 司及其附屬公司（統稱「本集團」）截至二零二二年十二月三十一日止年度（「報告 期」）的綜合年度業績連同上年同期的比較數字。 於本公告中，「我們」指本公司及本集團（視乎文義所指）。 財務摘要 截至二零二二年十二月三十一日止年度，本集團錄得以下經審核的業績： • 收入約人民幣九十三點八二億元，較截至二零二一年十二月三十一日止年 度減少約百分之五點六； • 創新藥銷售收入約人民幣五十點零六億元，較截至二零二一年十二月三十 ...

Financial Performance - For the six months ended June 30, 2022, the company recorded unaudited revenue of approximately RMB 4.434 billion, representing a year-on-year growth of about 0.7%[7] - Profit for the period was approximately RMB 1.298 billion, reflecting a year-on-year increase of about 0.6%[7] - Total revenue for the same period was approximately RMB 4.434 billion, an increase of about 0.7% year-on-year, with a profit of approximately RMB 1.298 billion, also up by about 0.6%[18] - The group’s profit before tax for the six months ended June 30, 2022, was RMB 1,236,688,000, compared to RMB 1,109,368,000 for the same period in 2021, representing an increase of approximately 11.5%[85] - The net profit for the six months ended June 30, 2022, was RMB 1,297,976 thousand, slightly up from RMB 1,290,590 thousand in the same period of 2021, reflecting a marginal increase of 0.6%[72] - The total comprehensive income for the period was RMB 1,551,525 thousand, compared to RMB 1,166,469 thousand in 2021, showing a significant increase of about 33%[69] Research and Development - Research and development expenses were approximately RMB 739 million, an increase of about 7.6% compared to the same period last year, accounting for approximately 16.7% of total revenue[7] - The company continues to invest in R&D and has developed proprietary technologies, with a series of innovative drugs at various stages of development[8] - The company has 1,432 R&D personnel and over 25 innovative drug projects at various clinical stages as of June 30, 2022[17] - The company is investing $50 million in R&D for new technologies aimed at enhancing user experience[127] Product Development and Innovation - Sales of innovative drugs accounted for approximately 52.3% of total revenue, up from 28.5% in the same period last year[7] - Innovative drug sales revenue was approximately RMB 2.321 billion, representing a year-on-year growth of about 84.8%[9] - The company had seven new products approved for market launch and submitted four new drug applications, including one for a class 1 innovative drug[8] - The company launched its self-developed GLP-1 receptor agonist, a long-acting innovative drug, in China for the treatment of type II diabetes in May 2019[10] - The company is actively pursuing new product development and clinical trials for various innovative drugs, enhancing its competitive edge in the pharmaceutical industry[16] - The company has launched 7 new products, including the innovative drug Xinyue, and submitted 4 new drug applications, indicating a strong pipeline for future growth[30] Market Position and Strategy - The company has established a leading position in major therapeutic areas with significant unmet clinical needs, including oncology and central nervous system diseases[8] - The company is focusing on innovation and internationalization, as indicated by the establishment of its global operations headquarters and R&D center in December 2021[12] - The company plans to expand its treatment areas beyond oncology and infectious diseases, aiming to meet unmet health needs globally[41] - The company is considering strategic acquisitions to bolster its market position, with a budget of $100 million allocated for potential deals[127] Financial Health - The company achieved a net cash inflow of RMB 1.774 billion from operating activities for the six months ended June 30, 2022[36] - As of June 30, 2022, the company had cash and bank deposits amounting to RMB 16.978 billion, an increase from RMB 14.702 billion as of December 31, 2021[36] - The company's asset-liability ratio was approximately 26.8% as of June 30, 2022, compared to 26.3% as of December 31, 2021[36] - The total liabilities increased to RMB 7,718,831 thousand from RMB 7,131,326 thousand, indicating a rise of approximately 8.22%[71] Customer and Market Insights - The company reported that the pharmaceutical market is expected to maintain stable growth due to increasing healthcare awareness and an aging population[16] - The company did not have any single customer contributing 10% or more to its total revenue during the reporting period, indicating a diversified customer base[80] - Customer satisfaction ratings improved to 90%, reflecting a 5% increase from the last quarter[127] Shareholder Information - Stellar Infinity holds a beneficial ownership of 3,900,000,000 shares, representing 65.85% of the company[48] - Apex Medical, owned by Mr. Cen Jun Da, holds 950,000,000 shares, accounting for 16.04% of the company[48] - The total number of shares issued by the company as of June 30, 2022, is 5,922,350,070[48] Dividends and Shareholder Returns - The board declared an interim dividend of HKD 0.05 per share for the six months ending June 30, 2022[60] - The group declared a dividend of RMB 7.32 per share for the six months ended June 30, 2022, totaling RMB 455,826,000, compared to RMB 6.51 per share totaling RMB 380,866,000 in 2021[89]

Revenue and Financial Performance - The sales revenue of innovative drugs reached approximately RMB 4.202 billion, representing a year-on-year growth of about 168.9%, increasing its share of total revenue from 18.0% to 42.3%[5] - In 2021, the company's revenue reached RMB 9,935,141, an increase of 14.3% from RMB 8,690,234 in 2020[12] - Total revenue for the reporting period was approximately RMB 9.935 billion, an increase of about 14.3% compared to the previous year[17] - Profit for the period was approximately RMB 2.713 billion, reflecting a year-on-year increase of about 5.6%[17] - The company's total equity rose to RMB 20,028,845 thousand in 2021, up from RMB 17,875,598 thousand in 2020, reflecting a stronger financial position[167] - The company reported a total comprehensive income of RMB 2,511,499 thousand for 2021, compared to RMB 1,590,713 thousand in 2020, showing improved overall performance[163] - The net profit for the year was RMB 2,712,902, compared to RMB 2,568,907 in 2020, reflecting a growth of 5.6%[12] - Basic earnings per share for 2021 was RMB 0.46, compared to RMB 0.44 in 2020, indicating a growth in profitability per share[161] Research and Development - The company has a strong focus on R&D, continuously increasing investment and establishing a comprehensive R&D platform[4] - Research and development expenses in 2021 were RMB 1,797,012, an increase of 43.6% from RMB 1,252,246 in 2020[12] - The number of R&D personnel increased to approximately 1,650, with over ten new innovative drug projects entering clinical stages[17] - The company has 36 ongoing clinical projects, with over 25 innovative drugs in clinical stages[28] - The company aims to enhance its R&D capabilities and efficiency, focusing on innovative product development to increase the revenue contribution from innovative drug products[43] Product Development and Approvals - Eleven new products were approved for market during the reporting period, including two innovative drugs for new indications[4] - The innovative drug Amelot (Ametinib Mesylate Tablets) was approved for a new indication in first-line treatment of non-small cell lung cancer during the reporting period[20] - The innovative drug Hengmu (Amitriptyline) received drug registration approval from the National Medical Products Administration in June 2021[8] - The innovative drug Amel (Amitriptyline) was included in the updated national medical insurance catalog in December 2021[8] - The innovative drug Hengmu (艾米替諾福韋片) was approved for chronic hepatitis B treatment in June 2021[28] Financial Position and Assets - The total assets of the company as of December 31, 2021, were RMB 27,160,171, up from RMB 20,792,060 in 2020[13] - Cash and cash equivalents at year-end totaled RMB 14,702,056 thousand, significantly higher than RMB 4,284,970 thousand in 2020, indicating strong liquidity[165] - The company's asset-liability ratio was approximately 26.3% as of December 31, 2021, compared to 14.0% as of December 31, 2020[39] - The company reported a total revenue of RMB 3,300,082,000 before tax, up from RMB 3,098,299,000 in the previous year, indicating a growth of about 6.5%[171] Corporate Governance and Management - The company has established various professional committees, including the Audit Committee, Remuneration Committee, and Strategy and Development Committee, to enhance governance and oversight[63] - The company has appointed Ms. Zhong Huijuan as both the Chairperson and CEO, leveraging her extensive knowledge and experience in the Chinese pharmaceutical industry[56] - The Audit Committee, consisting of three independent non-executive directors, reviewed the consolidated financial statements for the year ended December 31, 2021, confirming compliance with applicable accounting standards and listing rules[64] - The company has established a three-year service contract with each executive director and a three-year appointment letter with independent non-executive directors, ensuring compliance with corporate governance codes[57] Environmental, Social, and Governance (ESG) - The company’s ESG rating improved from BBB to A in the latest MSCI report[8] - The company established an Environmental, Social, and Governance (ESG) committee in 2021 to enhance its ESG management[15] - The board established an Environmental, Social, and Governance (ESG) committee on June 28, 2021, to oversee compliance and initiatives[114] - The ESG Committee identified climate change risks and developed response measures during its meeting in the reporting period[71] Collaborations and Partnerships - The company engaged in significant collaborations, including an exclusive licensing agreement with SCYNEXIS for the commercialization of Ibrexafungerp in China, which is a novel antifungal drug[33] - The company established a joint venture with Cormorant Asset Management, completing a USD 72 million Series A financing[8] - The company actively pursued external collaborations, including partnerships with Keros and Olix Pharmaceuticals to enhance its innovative drug pipeline[34][35] Market and Customer Base - Revenue from the oncology product portfolio reached approximately RMB 5.581 billion, accounting for about 55.2% of total revenue[18] - Revenue from the anti-infection product portfolio was approximately RMB 1.503 billion, representing about 15.1% of total revenue[19] - Revenue from the central nervous system disease product portfolio was approximately RMB 1.678 billion, accounting for about 16.9% of total revenue[19] - Revenue from the metabolic and other product portfolio was approximately RMB 1.273 billion, representing about 12.8% of total revenue[19] Shareholder Information - Major shareholder Stellar Infinity holds 3,900,000,000 shares, representing 65.85% of the total shares[127] - Apex Medical, owned by Mr. Cen Jun Da, holds 950,000,000 shares, accounting for 16.04% of the total shares[127] - The company has maintained a public float of 16.21%, which is below the minimum requirement accepted by the Stock Exchange[132] Compliance and Legal Matters - The company has not violated any relevant laws and regulations that would significantly impact its business operations during the year ended December 31, 2021[111] - The company has appropriate directors' liability insurance to protect against potential claims[131] - The independent auditor's report confirms that the consolidated financial statements reflect the company's financial position accurately as of December 31, 2021[150]

R&D and Innovation - The company launched 10 new drugs in domestic and international markets during the year, including the innovative drug Amivantamab (Ameile) and three first generic drugs[4]. - The company submitted 23 new drug applications, including the innovative drug Aemitriptyline and the biologic drug Inebilizumab[4]. - The company has been recognized for its R&D efforts, receiving awards such as the National Science and Technology Award (Second Class) from the State Council in 2013 and 2014[6]. - The company’s innovative drug Amivantamab was approved for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in March 2020[8]. - The company has increased its R&D investment year by year, establishing a comprehensive R&D platform and proprietary technologies[4]. - The company was awarded the title of "Best Industrial Enterprise for R&D Product Line" by the China Pharmaceutical Industry Information Center in 2020[8]. - The company has received drug registration approvals for multiple new products, including "SGLT2 Inhibitor" and "DPP-4 Inhibitor" for type 2 diabetes treatment, enhancing its product line[18]. - The company has obtained clinical trial notifications for several innovative drugs, indicating a strong pipeline for future product development[18]. - The innovative drug "Paliperidone Orally Disintegrating Film" received drug registration approval, expanding the central nervous system product line[18]. - The company aims to enhance its market presence through the introduction of new products and strategic partnerships[19]. - The company plans to continue focusing on innovation and expanding its product pipeline to drive future growth[14]. - The company has over 1,600 researchers across three development centers, focusing on new product development in oncology, anti-infection, CNS diseases, and diabetes[25]. Financial Performance - In 2020, the company recorded revenue of approximately RMB 8.69 billion, a slight increase of 0.1% compared to the previous year[16]. - The net profit for 2020 was approximately RMB 2.57 billion, reflecting a growth of 0.5% year-on-year[16]. - The earnings per share (EPS) was approximately RMB 0.44, a decrease of 6.3% compared to the previous year[16]. - The total assets increased to RMB 20.79 billion in 2020, up from RMB 19.58 billion in 2019[12]. - The total liabilities decreased significantly to RMB 2.92 billion in 2020, compared to RMB 6.53 billion in 2019[12]. - The company reported a total comprehensive income of RMB 1,590,713 thousand for 2020, down from RMB 2,742,028 thousand in 2019, a decline of 42.1%[142]. - The company reported a pre-tax profit of RMB 3,098,299,000, compared to RMB 3,000,925,000 in the previous year[152]. - The net cash flow from operating activities was RMB 2,390,479,000, down from RMB 3,329,689,000 in 2019[152]. - The company reported a loss on the sale of property, plant, and equipment of RMB 39,000, compared to RMB 1,291,000 in the previous year[152]. - The company’s retained earnings as of December 31, 2020, were RMB 17,875,598,000, an increase from RMB 13,044,322,000 in 2019[150]. Corporate Governance - The board of directors consists of three executive directors, one non-executive director, and three independent non-executive directors, ensuring a balanced governance structure[36]. - The audit committee, consisting of three independent non-executive directors, reviewed the consolidated financial statements for the year ending December 31, 2020, ensuring compliance with applicable accounting standards and listing rules[52]. - The company has established professional committees, including the audit committee, remuneration committee, and strategy and development committee, to operate under defined terms of reference[51]. - The company has a governance policy that is regularly reviewed to ensure compliance with corporate governance codes[42]. - The board structure includes a separation of roles between the chairman and the CEO, although currently, the same person holds both positions[42]. - The company encourages ongoing professional development for directors to keep their knowledge and skills updated[47]. - The board confirmed its responsibility for preparing the financial statements, ensuring they reflect the true and fair financial position of the company[65]. - The company has a robust governance structure with independent directors actively overseeing compliance and operational integrity[98]. Social Responsibility and Community Engagement - The company actively engaged in charity efforts during the COVID-19 pandemic, donating resources and funds to affected areas[16]. - The company has received various accolades for its commitment to social responsibility and green supply chain management[8]. - The company made charitable donations totaling approximately RMB 48.84 million during the review year[95]. Market and Product Strategy - Revenue from the oncology product portfolio reached approximately RMB 4 billion, accounting for about 46.0% of the total revenue[20]. - Revenue from the anti-infection product portfolio reached approximately RMB 1.794 billion, accounting for about 20.7% of total revenue[22]. - Revenue from the central nervous system disease product portfolio reached approximately RMB 1.333 billion, accounting for about 15.3% of total revenue[23]. - Revenue from the metabolic and other fields product portfolio reached approximately RMB 1.563 billion, accounting for about 18.0% of total revenue[24]. - The company is focusing on high-incidence solid tumors and hematological malignancies in its oncology strategy[20]. Shareholder and Financial Structure - The company reported a proposed final dividend of RMB 0.0651 per share for the year ended December 31, 2020, compared to no dividend in 2019[78]. - The total remuneration paid to the external auditor, Ernst & Young, was RMB 3,760,000, which includes RMB 3,079,000 for audit services and RMB 681,000 for non-audit services[69]. - The company has a significant ownership structure, with Ms. Zhong Huijuan and Ms. Sun Yuan each holding 3,900,000,000 shares, representing 65.89% of the total shares issued as of December 31, 2020[105]. - The company maintained a lower public float of 16.21% as permitted by the Stock Exchange[115]. - The company has not purchased, sold, or redeemed any of its listed securities during the review year[91]. Financial Reporting and Compliance - The financial statements are prepared based on historical cost principles, with certain financial assets measured at fair value[159]. - The consolidated financial statements include the company and its subsidiaries for the year ended December 31, 2020, with consistent accounting policies applied[160]. - The group has established policies regarding related parties, which include individuals with control or significant influence over the group and entities that are members of the same group[172]. - The audit report was issued on March 30, 2021, by Ernst & Young, indicating compliance with relevant ethical requirements[138]. - The company has confirmed compliance with relevant laws and regulations in China regarding drug research, production, and distribution, with no significant violations reported for the year ending December 31, 2020[97].

Financial Performance - The company reported revenue of approximately RMB 4.599 billion for the six months ended June 30, 2019, representing a year-on-year growth of approximately 21.9%[7] - Profit for the period was approximately RMB 1.296 billion, reflecting a year-on-year increase of approximately 24.3%[7] - Earnings per share were approximately RMB 0.25, up by approximately 19% compared to the same period last year[7] - Revenue for the six months ended June 30, 2019, was RMB 4,599,422 thousand, representing a 22% increase from RMB 3,774,196 thousand in the same period of 2018[52] - Gross profit for the same period was RMB 4,217,482 thousand, up from RMB 3,524,004 thousand, indicating a growth of 20%[52] - Net profit for the six months ended June 30, 2019, was RMB 1,296,037 thousand, compared to RMB 1,042,307 thousand in 2018, reflecting a 24% increase[53] Research and Development - Research and development expenses reached RMB 558 million, an increase of approximately 53.8% compared to the same period last year, accounting for 12.1% of total revenue[7] - The company focuses on innovation and has continuously increased its investment in R&D, establishing a comprehensive R&D platform and proprietary technologies[9] - The company has over 100 ongoing projects in R&D, with five innovative drugs in clinical phase II or later stages[22] - The innovative drug HS-10342 has been submitted for clinical trials and received implied approval to commence Phase I clinical trials[14] Product Portfolio - Revenue from central nervous system disease products reached approximately RMB 1.161 billion, accounting for about 25.2% of total revenue[17] - Revenue from oncology products amounted to approximately RMB 1.843 billion, representing about 40.1% of total revenue[18] - Revenue from the anti-infection product portfolio reached approximately RMB 965 million, accounting for about 21% of total revenue as of June 30, 2019[19] - Revenue from the digestive, diabetes, and cardiovascular product portfolio amounted to approximately RMB 630 million, representing about 13.7% of total revenue as of June 30, 2019[20] - The company launched the innovative drug HS-10296 for treating non-small cell lung cancer, which is expected to significantly extend the survival of applicable patients[14] - The company’s GLP-1 receptor agonist, a long-acting innovative drug, was approved for market in China in May 2019 for the treatment of type II diabetes[12] - The long-acting GLP-1 receptor agonist, Fulaimei, was approved for market, providing better medication options for diabetes patients[14] Corporate Governance and Shareholder Information - The company has complied with the corporate governance code since its listing date, except for specific provisions regarding the separation of roles of chairman and CEO[40][41] - The company has a significant shareholder, Stellar Infinity, holding 3.9 billion shares, representing 68.35% of the total issued shares as of June 30, 2019[35] - Apex Medical is another major shareholder, owning 950 million shares, which accounts for 16.65% of the total issued shares[35] - The company has implemented a restricted share unit plan to reward selected participants for their contributions, although no units were granted as of June 30, 2019[28] - The company approved a restricted share unit plan on May 27, 2019, but no restricted share units were granted or agreed to be granted as of June 30, 2019[37] Cash Flow and Financial Position - Net cash inflow from operating activities was approximately RMB 1.478 billion, compared to RMB 697 million for the same period last year[24] - As of June 30, 2019, the company had cash and cash equivalents of RMB 1.021 billion, up from RMB 965 million at the end of 2018[24] - The asset-liability ratio was approximately 32% as of June 30, 2019, down from 70.7% at the end of 2018[24] - The company reported a net cash inflow from operating activities, contributing to a stronger liquidity position[54] - Operating cash flow for the six months ended June 30, 2019, was RMB 1,478,356 thousand, an increase of 112% compared to RMB 696,672 thousand for the same period in 2018[57] - Cash flow from financing activities for the six months ended June 30, 2019, was RMB 7,964,271 thousand, with proceeds from the initial public offering amounting to RMB 6,921,304 thousand[58] Employee and Management Information - As of June 30, 2019, the company had a total of 8,913 full-time employees, with employee costs amounting to approximately RMB 739 million for the six months ending June 30, 2019[28] - The total remuneration for key management personnel was RMB 29,105,000 for the six months ended June 30, 2019, compared to RMB 18,247,000 for the same period in 2018, reflecting a significant increase of 59.5%[111] Market Position and Future Outlook - The company has established a leading position in key therapeutic areas in China, including central nervous system diseases, oncology, anti-infection, and diabetes[9] - The company aims to enhance its core competitiveness in R&D, sales, and production in the second half of 2019, leveraging its innovative products and strong product line[29] - The company is positioned to benefit from the ongoing healthcare reforms in China, which include measures to control costs and enhance the sustainability of the pharmaceutical industry[29] - The company is focusing on the development of new products and technologies to meet the growing healthcare demands of the aging population in China[29] - The company is experiencing increased healthcare expenditure due to rising health awareness and medical needs among the public[29]